CANY
AERI

Caxton Associates (New York)’s Aerie Pharmaceuticals AERI Stock Holding History

Caxton Associates (New York)’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60,974
Closed -$923K – 651
2022
Q3 		$923K Buy
60,974
+29,458
+93% +$342K 0.12% 134
2022
Q2 		$236K Buy
+31,516
New +$222K 0.02% 438

Caxton Associates (New York)'s AERI Position: Q4 2022 in Review

Caxton Associates (New York) sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 60,974 shares — an estimated $923K sold.

Caxton Associates (New York) first reported a position in AERI in Q2 2022 and held it in 2 quarters. The position peaked at $923K in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • Caxton Associates (New York) reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 60,974 Aerie Pharmaceuticals shares in Q4 2022, an estimated $923K.
  • Caxton Associates (New York) first reported a position in Aerie Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s Aerie Pharmaceuticals position peaked at $923K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Caxton Associates (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.